A paradigm shift in the understanding of melasma is changing the way dermatology clinicians approach the condition. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Dr. Mukta Sachdev, head of the department of dermatology at Manipal Hospital, Bangalore, India. Watch as Dr. Sachdev shares why photoprotection, barrier function, and pollution are some of the factors to consider in patients with melasma. Learn about the role of procedures in melasma management and why Dr. Sachdev says flexibility is key. Plus learn why the future of melasma treatment may involve gene therapy.
Further Reading
If you want to read more about melasma, check out the following articles published in the Journal of Drugs in Dermatology:
ABSTRACT
Background: Melasma is a chronic pigmentary disorder. In this study, an innovative cream combining cysteamine and tranexamic acid (TXA) was assessed.
Objective: To evaluate the safety, efficacy, and patient satisfaction of a novel nano-formulated cysteamine and TXA combination cream in treating subjects with epidermal melasma.
Methods: Fifty (50) randomized subjects participated and received cysteamine and TXA combination cream. The cream was applied for 30 minutes daily for a 3-month duration. Treatment effectiveness, safety, patient satisfaction, and adherence were evaluated.
Results: A continuous improvement in melasma was observed, with modified Melasma Area and Severity Index (mMASI) scores improving by 40%, 57%, and 63% at 30, 60, and 90 days, respectively. The primary endpoint of a decrease in mMASI scores was met, with 91% of participants experiencing melasma improvement. Patient Satisfaction and Patient Adherence scores indicated satisfaction. Convenience exhibited the strongest correlation with patient adherence.
Conclusion: Nano-formulated cysteamine and TXA combination cream showed significant efficacy in decreasing mMASI score while demonstrating a strong safety profile and patient satisfaction.
Oral Tranexamic Acid for the Treatment of Melasma: A Case Series and Novel Dosing Regimen
ABSTRACT
Melasma is a common disorder affecting millions of people around the world. It is a condition that can disrupt one’s self-esteem and overall quality of life. Melasma is characterized by hyperpigmented macules and patches on the face. The pathophysiology of melasma is widely unknown, although multiple triggers have been identified. Among the triggers, sun exposure is considered to be the most important factor. A variety of topical treatments exist for melasma, however most of these options often lead to subpar results. Due to this, novel treatments such as oral tranexamic acid (TXA) have emerged. Our case series demonstrates the effectiveness and safety profile of utilizing oral TXA to treat recalcitrant melasma and highlights a possible dosing regimen that can be used for the novel therapy.
Did you enjoy this video interview? Find more here.
